Nevro Corp. (NYSE:NVRO) this week promoted president Rami Elghandour to be its new CEO, as chief executive Michael DeMane moves to the executive chairman spot. DeMane, the former COO at Medtronic, will keep an active role in Nevro, which he joined in 2011 after a quickly aborted stint at the head of Lanx. He’s due to […]
Nevro Corp. (NYSE:NVRO) yesterday beat a pair of challenges to 1 of its patents by Boston Scientific (NYSE:BSX), after the U.S. Patent & Trademark office declined to institute inter partes reviews. Nevro’s Senza device, which won pre-market approval from the FDA in May, is designed to deliver up to 10,000Hz to the spinal cord, allowing it to avoid the […]
Nevro Corp. (NYSE:NVRO) appears to have the upper hand in a patent challenge from Boston Scientific (NYSE:BSX) over its Senza chronic pain device, according to patent attorneys interviewed by Leerink Partners analyst Danielle Antalffy. Nevro’s Senza device, which won premarket approval from the FDA, is designed to deliver up to 10,000Hz to the spinal cord, allowing it to […]
Zimmer (NYSE:ZMH), who acquired Biomet in a deal that closed this month, announced a series of personnel shifts upon the closure of the merger. Zimmer CFO and senior veep James Crines has stepped down from his position to retire, effective August 3, to be replaced by former CFO and senior veep of BiometDaniel Florin, the company said. […]
A trio of medical device companies that went public last year are planning follow-on offerings to raise more cash. Nevro Corp. (NYSE:NVRO), Intersect ENT (NSDQ:XENT) and Ocular Therapeutix (NSDQ:OCUL) all revealed plans for the flotations this week. Menlo Park, Calif.-based Nevro priced its 1.8-million-share offering yesterday at $51 per share, saying stockholders would put up another […]
With 2014 a rebounding year for medical device and biopharmaceutical IPOs, 2015 should build further on that progress, a panel at the MedTech Investing Conference said this week.